Moderna joins Nasdaq-100 as Moderna stock trades at EUR 192.95

Published on 10/19/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna joined the Nasdaq-100 on October 9, 2026. Moderna stock costs EUR 192.95 on October 19, 2026, while Q2 revenue was USD 145.0 million.

Index membership and operating scale

Nasdaq added Moderna to the Nasdaq-100 on October 9, 2026.
Second-quarter 2026 revenue reached USD 145.0 million.
Moderna stock trades at EUR 192.95 at 10:03 a.m. CEST at Lang & Schwarz on October 19, 2026.
Moderna will report third-quarter 2026 results on November 6, 2026.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna, Inc. (ISIN US60770K1079) was trading at EUR 192.95 at Lang & Schwarz on October 19, 2026, at 10:03 a.m. CEST, while Nasdaq added the biotechnology company to the Nasdaq-100 on October 9, 2026. The index inclusion gives the stock a broader benchmark connection as Moderna prepares for its next results update.

Nasdaq-100 inclusion changes the backdrop

The Nasdaq release dated October 1, 2026 said Moderna would replace Warner Bros. Discovery in the index before the market opened on October 9. The announcement also explicitly identified Moderna as a Nasdaq-listed company under ticker MRNA.

The company enters the index with a substantial clinical and commercial pipeline. Moderna's corporate website lists 45 development programs and 36 ongoing clinical trials, while its mission centers on messenger RNA medicines for infectious diseases, cancer and other medical needs.

Three milestones define the recent picture

On July 31, 2026, Moderna reported second-quarter revenue of USD 145.0 million, a GAAP net loss of USD 782.0 million and diluted GAAP earnings per share of minus USD 1.97, according to Access Newswire. Revenue was 2.1 percent above the second quarter of 2025, while the loss narrowed by 5.2 percent.

On October 1, Nasdaq announced Moderna's upcoming index membership. On October 13, Moderna announced that it would report third-quarter 2026 results on November 6. The sequence links a completed benchmark change with the next financial checkpoint.

What does the second quarter mean?

Moderna's second-quarter revenue was smaller than its first-quarter revenue of USD 389.0 million, a decrease of 62.7 percent. However, management reiterated its plan for revenue growth of up to 10 percent in 2026 and projected year-end cash and investments of USD 4.7 billion to USD 5.2 billion, according to the company's earnings-call transcript published by Yahoo Finance. The figures leave product launches, seasonal demand and cost control as central variables for the next report.

Two dates set the next checkpoints

Moderna will report third-quarter 2026 financial results on November 6, 2026, with the call scheduled for 8:00 a.m. ET, according to Access Newswire. An analyst day is scheduled for November 12, 2026, according to Simply Wall St.

Market value remains tied to execution

Moderna's market capitalization was USD 87.0 billion as of October 16, 2026, and its 52-week range was USD 22.28 to USD 242.29. The share price therefore stood USD 49.34 below the recorded high, a distance of 20.36 percent. For investors, the November results will provide the next quantified test of the growth plan behind the index inclusion.

Moderna was trading at EUR 192.95 at Lang & Schwarz on October 19, 2026, at 10:03 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.